Compare iShares MSCI Indonesia ETF (EIDO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Sana Biotechnology Inc — how do they compare? iShares MSCI Indonesia ETF trades at $11.98 (market cap $409.22M), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Sana Biotechnology Inc is far larger — about 2× iShares MSCI Indonesia ETF's market cap, and iShares MSCI Indonesia ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Sana Biotechnology Inc for 23 Days on average.
| EIDO | SANA | |
|---|---|---|
Market Cap | $409.22M | $836.71M |
Volume | 879,527 | 4,507,444 |
52-Week High | $19.22 | $5.92 |
52-Week Low | $10.80 | $2.68 |
Typical Hold Time | 76 Days | 23 Days |
Sector | — | Health |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $11.87, showing minimal daily movement with a 0.08% gain. Technical indicators signal a bearish trend, with moving averages and ADX pointing downward, though RSI levels hint at potential oversold conditions. Recent news highlights underperformance amid sector rotation away from Asian equities, with volume declining 21% below average. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to weak price action and bearish technicals. Risks include high financials exposure and slow EPS growth. Upside may depend on seasonal trends or valuation support, but current sentiment and institutional flows suggest continued pressure. Investors should weigh technical weakness against potential bargain opportunities.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
